Testing effectiveness (Phase 2)Study completedNCT04836858
What this trial is testing
Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
Who this might be right for
Atopic Dermatitis
Novartis Pharmaceuticals 71